DOCSLIB.ORG

Ep 2368547 B1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 2368547 B1 (19) & (11) EP 2 368 547 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/045 (2006.01) A61K 31/122 (2006.01) 12.09.2012 Bulletin 2012/37 A61P 31/12 (2006.01) A61P 31/14 (2006.01) A61P 31/16 (2006.01) A61P 31/18 (2006.01) (2006.01) (2006.01) (21) Application number: 10157930.8 A61P 31/20 A61P 31/22 (22) Date of filing: 26.03.2010 (54) Antiviral compositions comprising geraniol and carvone Geraniol und Carvon enthaltende antivirale Zubereitungen Compositions antivirales comprenantes la géraniol et la carvone (84) Designated Contracting States: • RAINA V K ET AL: "ESSENTIAL OIL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR COMPOSITION OF CURCUMA LONGA L. CV. HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL ROMAFROM THE PLAINS OF NORTHERN INDIA" PT RO SE SI SK SM TR FLAVOUR AND FRAGRANCE JOURNAL, WILEY, Designated Extension States: NEW YORK, NY, GB LNKD- DOI:10.1002/FFJ. AL BA ME RS 1053, vol. 17, 1 January 2002 (2002-01-01), pages 99-102, XP009036568 ISSN: 0882-5734 (43) Date of publication of application: • BOURNE K Z ET AL: "Plant products as topical 28.09.2011 Bulletin 2011/39 microbicide candidates: Assessment of in vitro and in vivo activity against herpes simplex virus (73) Proprietor: Cesa Alliance S.A. type 2" ANTIVIRAL RESEARCH 199907 NL LNKD- 8041 Strassen (LU) DOI:10.1016/S0166-3542(99)00020-0, vol. 42, no. 3, July 1999 (1999-07), pages 219-226, (72) Inventor: Coppens, Christine XP002579480 ISSN: 0166-3542 8041, Strassen (LU) • PADUCH R ET AL: "Terpenes: Substances useful in human healthcare" ARCHIVUM (74) Representative: Fichter, Robert Arno IMMUNOLOGIAE ET THERAPIAE Dennemeyer & Associates S.A. EXPERIMENTALIS 200710 CH LNKD- DOI: 55, rue des Bruyères 10.1007/S00005-007-0039-1, vol. 55, no. 5, 1274 Howald (LU) October 2007 (2007-10), pages 315-327, XP002579481 ISSN: 0004-069X (56) References cited: • HAYASHI S ET AL: "Adenovirus infections and WO-A1-02/056879 US-A- 3 429 971 lung disease", CURRENT OPINION IN US-A- 4 402 950 PHARMACOLOGY - RESPIRATORY/ MUSCULOSKELETAL 200706 GB LNKD- DOI: • CHIANG L -C ET AL: "Antiviral activities of 10.1016/J.COPH.2006.11.014, vol. 7, no. 3, June extracts and selected pure constituents of 2007 (2007-06), pages 237-243, XPXP022078318, Ocimum basilicum" CLINICAL AND ISSN: 1471-4892 EXPERIMENTAL PHARMACOLOGY AND • CROWELL P L ET AL: "Structure-activity PHYSIOLOGY 200510 AU LNKD- DOI:10.1111/J. relationships among monoterpene inhibitors of 1440-1681.2005.04270.X, vol. 32, no. 10, October protein isoprenylation and cell proliferation", 2005 (2005-10), pages 811-816, XP002579479 BIOCHEMICAL PHARMACOLOGY, PERGAMON, ISSN: 0305-1870 OXFORD, GB LNKD- DOI:10.1016/0006-2952(94) • KAUL P N ET AL: "The essential oil composition 90341-7, vol. 47, no. 8, 20 April 1994 (1994-04-20) , of Angelica glauca roots" PLANTA MEDICA, pages 1405-1415, XP023737606, ISSN: 0006-2952 THIEME VERLAG, DE, vol. 62, no. 1, 1 January [retrieved on 1994-04-20] 1996 (1996-01-01), pages 80-81, XP009132565 ISSN: 0032-0943 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 368 547 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 368 547 B1 • BENENCIA F ET AL: "IN VITRO AND IN VIVO • ’Anti-Viral Elixir (Herpes Treatment)’, [Online] ACTIVITY OF EUGENOL ON HUMAN INTERNET, Retrieved from the Internet: <URL: HERPESVIRUS", PHYTOTHERAPY RESEARCH, http://web.archive.org/web/20100212155 JOHN WILEY & SONS LTD. CHICHESTER, GB, 404/http://barlowesherbalelixirs.com/anti-v vol. 14, no. 7, 1 January 2000 (2000-01-01), pages iral.html> 495-500, XP008057336, ISSN: 0951-418X, DOI: • A. Ranalli ET AL: "Analytical Evaluation of Virgin DOI:10.1002/1099-1573(200011)14:7<495::AID Olive Oil of First and Second Extraction", Journal -PTR650>3.0.CO;2-8 of Agricultural and Food Chemistry, vol. 47, no. • RYABCHENKO B ET AL: "Investigation of 2, 1 February 1999 (1999-02-01), pages 417-424, anticancer and antiviral properties of selected XP55027770, ISSN: 0021-8561, DOI: aroma samples", NATURAL PRODUCT 10.1021/jf9800256 COMMUNICATIONS, NATURAL PRODUCT INC, US, vol. 3, no. 7, 1 January 2008 (2008-01-01) , Remarks: pages 1085-1088, XP009143771, ISSN: 1934-578X Thefile contains technical information submitted after the application was filed and not included in this specification 2 EP 2 368 547 B1 Description Field of the invention: 5 [0001] The present invention relates to the pharmaceutical field. [0002] The present invention relates to a composition for use in treatment and prevention of diseases caused by DNA enveloped, DNA non-enveloped, RNA enveloped, RNA non-enveloped viruses according to claim 1, a composition for use as a prophylactic according to claim 3, use of the composition as a disinfectant according to claim 6, a composition for use as a viral inhibitor according to claim 4, use of the composition as a viral inhibitor outside the body according to 10 claim 7. Background of invention: [0003] US 4402950 concerns a process and a preparation for deactivating viruses inside living human and animal 15 organisms by application of a terpene obtainable from aromatic plants by steam distillation. The terpenes cited are: black pepper oil, cinnamon flower oil, cardamon oil, linallyl acetate, cinnamic aldehyde, safrol, carvon and cis/trans citral. [0004] US 3429971 discloses a pharmaceutical composition comprising cis-2,6-di-methyl-2,6-octadiène-8-ol as the active ingredient. This medicament is effective to treat avian lymphomatosis virus strain ES4. [0005] WO 2009148280 relates to use of a diaryl hepatonoid-based compound for inhibiting virus activity. The diaryl 20 hepatonoid-based compound has excellent inhibitory effects on virus activity, so it can be used as a therapeutic agent for virus-related diseases. [0006] WO 2009148279 relates to an application for a triterpenoid- based compound for suppressing viral activity. The triterpenold-based compound is outstandingly effective in suppressing viral activity and can therefore be beneficially used as a therapeutic agent for medical conditions in which a virus is involved. 25 [0007] An extensive literature search did not find any evidence of a significant amount of 2-methyl-5-(prop-1-en-2- yl)-cyclohex-2-enone and (2E)-3,7-dimethylocta-2,6-dien-1-ol together, or both in combination with other components to produce a broad spectrum antiviral effect. Summary of the invention: 30 [0008] The composition for use in treatment and prevention of diseases caused by DNA enveloped, DNA non-envel- oped, RNA enveloped, RNA non-enveloped viruses of the present invention is defined in claim 1, a composition for use as a prophylactic of the present invention is defined in claim 3, the use of the composition of the present invention as a disinfectant is defined in claim 6, a composition for use as a viral inhibitor of the present invention is defined in claim 4, 35 the use of the composition of the present invention as a viral inhibitor outside the body is defined in claim 7. [0009] The technical effect of the present invention is to prevent viruses merging with the host cell(s) by interfering with the viral lipid envelope. [0010] The technical problem to be solved is to prevent the multiplication of the viruses In animals and human beings and therefore curing diseased animals or human beings. 40 [0011] To solve the problem, the present invention provides a composition according to claim 1. [0012] It is inferred from some scientific studies that non- enveloped viruses acquire a lipid envelope from the host and as the composition of the present invention interferes with this triglyceride envelope and the envelope of enveloped viruses, it can be declared that the composition of the present invention will de- activate all types of viruses in vivo within animals or human beings. 45 [0013] Following are the most common viruses that can be de- activated with the compositions according to the present invention. As the mode of action of the invention is non-specific, the virus species and serotype is irrelevant. The person skilled in the art knows that all viruses are classified into 4 major groups consisting of DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses. 50 [0014] All compositions of the present invention are pharmaceutical compositions in a pharmaceutically effective weight percentage which can treat animal and/or human diseases. List of diseases: 55 [0015] The compositions of the present invention are used for treating and preventing a disease related to one of the above mentioned viral groups as well as on diseases selected from the non exhaustive group consisting in: (bron- cho)-pneumonia, 3 day fever exanthema, acute and chronic hepatitis, acute fever, acute gastroenteritis caused by strains such as Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, acute gastroenteritis 3 EP 2 368 547 B1 caused by strains such as Houston/ 86 Houston/90 London 29845 Manchester Parkville Sapporo virus, acute hepatitis, acute respiratory distress syndrome, AIDS, anogenital mucosa, Argentine hemorrhagic fever, arthralgia, avian flu, Bo- livian hemorrhagic fever, Brazilian hemorrhagic fever, chickenpox, chronic hepatitis,
Load more

Recommended publications
  • Genetic Diversity of Dengue Virus in Clinical Specimens from Bangkok
    Tropical Medicine and Infectious Disease Article Genetic Diversity of Dengue Virus in Clinical Specimens from Bangkok, Thailand, during 2018–2020: Co-Circulation of All Four Serotypes with Multiple Genotypes and/or Clades Kanaporn Poltep 1,2,3 , Juthamas Phadungsombat 2,4 , Emi E. Nakayama 2,4 , Nathamon Kosoltanapiwat 1 , Borimas Hanboonkunupakarn 5, Witthawat Wiriyarat 3, Tatsuo Shioda 2,4,* and Pornsawan Leaungwutiwong 1,* 1 Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; kanaporn.pol@gmail.com (K.P.); nathamon.kos@mahidol.ac.th (N.K.) 2 Mahidol-Osaka Center for Infectious Diseases (MOCID), Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; juthamas@biken.osaka-u.ac.jp (J.P.); emien@biken.osaka-u.ac.jp (E.E.N.) 3 The Monitoring and Surveillance Center for Zoonotic Diseases in Wildlife and Exotic Animals, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom 73170, Thailand; witthawat.wir@mahidol.edu 4 Department of Viral Infections, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka 565-0871, Japan 5 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; borimas.han@mahidol.ac.th * Correspondence: shioda@biken.osaka-u.ac.jp (T.S.); pornsawan.lea@mahidol.ac.th (P.L.) Citation: Poltep, K.; Phadungsombat, Abstract: Dengue is an arboviral disease highly endemic in Bangkok, Thailand. To characterize J.; Nakayama, E.E.; Kosoltanapiwat, the current genetic diversity of dengue virus (DENV), we recruited patients with suspected DENV N.; Hanboonkunupakarn, B.; infection at the Hospital for Tropical Diseases, Bangkok, during 2018–2020. We determined complete Wiriyarat, W.; Shioda, T.; nucleotide sequences of the DENV envelope region for 111 of 276 participant serum samples.
    [Show full text]
  • Grapevine Virus Diseases: Economic Impact and Current Advances in Viral Prospection and Management1
    1/22 ISSN 0100-2945 http://dx.doi.org/10.1590/0100-29452017411 GRAPEVINE VIRUS DISEASES: ECONOMIC IMPACT AND CURRENT ADVANCES IN VIRAL PROSPECTION AND MANAGEMENT1 MARCOS FERNANDO BASSO2, THOR VINÍCIUS MArtins FAJARDO3, PASQUALE SALDARELLI4 ABSTRACT-Grapevine (Vitis spp.) is a major vegetative propagated fruit crop with high socioeconomic importance worldwide. It is susceptible to several graft-transmitted agents that cause several diseases and substantial crop losses, reducing fruit quality and plant vigor, and shorten the longevity of vines. The vegetative propagation and frequent exchanges of propagative material among countries contribute to spread these pathogens, favoring the emergence of complex diseases. Its perennial life cycle further accelerates the mixing and introduction of several viral agents into a single plant. Currently, approximately 65 viruses belonging to different families have been reported infecting grapevines, but not all cause economically relevant diseases. The grapevine leafroll, rugose wood complex, leaf degeneration and fleck diseases are the four main disorders having worldwide economic importance. In addition, new viral species and strains have been identified and associated with economically important constraints to grape production. In Brazilian vineyards, eighteen viruses, three viroids and two virus-like diseases had already their occurrence reported and were molecularly characterized. Here, we review the current knowledge of these viruses, report advances in their diagnosis and prospection of new species, and give indications about the management of the associated grapevine diseases. Index terms: Vegetative propagation, plant viruses, crop losses, berry quality, next-generation sequencing. VIROSES EM VIDEIRAS: IMPACTO ECONÔMICO E RECENTES AVANÇOS NA PROSPECÇÃO DE VÍRUS E MANEJO DAS DOENÇAS DE ORIGEM VIRAL RESUMO-A videira (Vitis spp.) é propagada vegetativamente e considerada uma das principais culturas frutíferas por sua importância socioeconômica mundial.
    [Show full text]
  • Changes to Virus Taxonomy 2004
    Arch Virol (2005) 150: 189–198 DOI 10.1007/s00705-004-0429-1 Changes to virus taxonomy 2004 M. A. Mayo (ICTV Secretary) Scottish Crop Research Institute, Invergowrie, Dundee, U.K. Received July 30, 2004; accepted September 25, 2004 Published online November 10, 2004 c Springer-Verlag 2004 This note presents a compilation of recent changes to virus taxonomy decided by voting by the ICTV membership following recommendations from the ICTV Executive Committee. The changes are presented in the Table as decisions promoted by the Subcommittees of the EC and are grouped according to the major hosts of the viruses involved. These new taxa will be presented in more detail in the 8th ICTV Report scheduled to be published near the end of 2004 (Fauquet et al., 2004). Fauquet, C.M., Mayo, M.A., Maniloff, J., Desselberger, U., and Ball, L.A. (eds) (2004). Virus Taxonomy, VIIIth Report of the ICTV. Elsevier/Academic Press, London, pp. 1258. Recent changes to virus taxonomy Viruses of vertebrates Family Arenaviridae • Designate Cupixi virus as a species in the genus Arenavirus • Designate Bear Canyon virus as a species in the genus Arenavirus • Designate Allpahuayo virus as a species in the genus Arenavirus Family Birnaviridae • Assign Blotched snakehead virus as an unassigned species in family Birnaviridae Family Circoviridae • Create a new genus (Anellovirus) with Torque teno virus as type species Family Coronaviridae • Recognize a new species Severe acute respiratory syndrome coronavirus in the genus Coro- navirus, family Coronaviridae, order Nidovirales
    [Show full text]
  • JOURNAL of VIROLOGY Volume 18 Contents for May Number 2
    JOURNAL OF VIROLOGY Volume 18 Contents for May Number 2 Animal Viruses Isolation and Properties of the Replicase of Encephalomyocarditis Virus. A. TRAUB,* B. DISKIN, H. ROSENBERG, AND E. KALMAR ...... ............... 375 Synthesis and Integration of Viral DNA in Chicken Cells at Different Times After Infection with Various Multiplicities of Avian Oncornavirus. ALLAN T. KHOURY* AND HIDESABURO HANAFUSA ........ .......................... 383 RNA Metabolism of Murine Leukemia Virus. III. Identification and Quantitation of Endogenous Virus-Specific mRNA in the Uninfected BALB/c Cell Line JLS-V9. HUNG FAN AND NIKOLAUS MUELLER-LANTZSCH* ..... ............ 401 Endogenous Ecotropic Mouse Type C Viruses Deficient in Replication and Produc- tion of XC Plaques. ULF W RAPP AND ROBERT C. NoWINSKI* ..... ....... 411 Further Characterization of the Friend Murine Leukemia Virus Reverse Tran- scriptase-RNase H Complex. KARIN MOELLING ...... ................... 418 State of the Viral DNA in Rat Cells Transformed by Polyoma Virus. I. Virus Res- cue and the Presence of Nonintegrated Viral DNA Molecules. ISHWARI PRASAD, DIMITRIS ZOUZIAS, AND CLAUDIO BASIUCO* ...... ................ 436 Inhibition of Infectious Rous Sarcoma Virus Production by a Rifamycin Deriva- tive. CHARLES SZABO,* MINA J. BISSELL, AND MELVIN CALVIN ..... ...... 445 Synthesis ofthe Adenovirus-Coded DNA Binding Protein in Infected Cells. ZVEE GILEAD,* KINJI SUGUWARA, G. SHANMUGAM, AND MAURICE GREEN ....... 454 Intracellular Distribution and Sedimentation Properties of Virus-Specific RNA in Two Clones of BHK Cells Transformed by Polyoma Virus. IAN H. MAX- WELL .............................................................. 461 Inherited Resistance to N- and B-Tropic Murine Leukemia Viruses In Vitro: Titration Patterns in Strains SIM and SIM.R Congenic at the Fv-1 Locus. VERA SCHUH, MARTIN E. BLACKSTEIN, AND ARTHUR A.
    [Show full text]
  • TNF Decoy Receptors Encoded by Poxviruses
    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; fj.alvarez@cbm.csic.es (F.J.A.-d.M.); ialonso@cbm.csic.es (I.A.-S.); aalcami@cbm.csic.es (A.A.) * Correspondence: bhernaez@cbm.csic.es; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
    [Show full text]
  • ICD-9 Diagnosis Codes Effective 10/1/2011 (V29.0) Source: Centers for Medicare and Medicaid Services
    ICD-9 Diagnosis Codes effective 10/1/2011 (v29.0) Source: Centers for Medicare and Medicaid Services 0010 Cholera d/t vib cholerae 00801 Int inf e coli entrpath 01086 Prim prg TB NEC-oth test 0011 Cholera d/t vib el tor 00802 Int inf e coli entrtoxgn 01090 Primary TB NOS-unspec 0019 Cholera NOS 00803 Int inf e coli entrnvsv 01091 Primary TB NOS-no exam 0020 Typhoid fever 00804 Int inf e coli entrhmrg 01092 Primary TB NOS-exam unkn 0021 Paratyphoid fever a 00809 Int inf e coli spcf NEC 01093 Primary TB NOS-micro dx 0022 Paratyphoid fever b 0081 Arizona enteritis 01094 Primary TB NOS-cult dx 0023 Paratyphoid fever c 0082 Aerobacter enteritis 01095 Primary TB NOS-histo dx 0029 Paratyphoid fever NOS 0083 Proteus enteritis 01096 Primary TB NOS-oth test 0030 Salmonella enteritis 00841 Staphylococc enteritis 01100 TB lung infiltr-unspec 0031 Salmonella septicemia 00842 Pseudomonas enteritis 01101 TB lung infiltr-no exam 00320 Local salmonella inf NOS 00843 Int infec campylobacter 01102 TB lung infiltr-exm unkn 00321 Salmonella meningitis 00844 Int inf yrsnia entrcltca 01103 TB lung infiltr-micro dx 00322 Salmonella pneumonia 00845 Int inf clstrdium dfcile 01104 TB lung infiltr-cult dx 00323 Salmonella arthritis 00846 Intes infec oth anerobes 01105 TB lung infiltr-histo dx 00324 Salmonella osteomyelitis 00847 Int inf oth grm neg bctr 01106 TB lung infiltr-oth test 00329 Local salmonella inf NEC 00849 Bacterial enteritis NEC 01110 TB lung nodular-unspec 0038 Salmonella infection NEC 0085 Bacterial enteritis NOS 01111 TB lung nodular-no exam 0039
    [Show full text]
  • Hantavirus Disease Were HPS Is More Common in Late Spring and Early Summer in Seropositive in One Study in the U.K
    Hantavirus Importance Hantaviruses are a large group of viruses that circulate asymptomatically in Disease rodents, insectivores and bats, but sometimes cause illnesses in humans. Some of these agents can occur in laboratory rodents or pet rats. Clinical cases in humans vary in Hantavirus Fever, severity: some hantaviruses tend to cause mild disease, typically with complete recovery; others frequently cause serious illnesses with case fatality rates of 30% or Hemorrhagic Fever with Renal higher. Hantavirus infections in people are fairly common in parts of Asia, Europe and Syndrome (HFRS), Nephropathia South America, but they seem to be less frequent in North America. Hantaviruses may Epidemica (NE), Hantavirus occasionally infect animals other than their usual hosts; however, there is currently no Pulmonary Syndrome (HPS), evidence that they cause any illnesses in these animals, with the possible exception of Hantavirus Cardiopulmonary nonhuman primates. Syndrome, Hemorrhagic Nephrosonephritis, Epidemic Etiology Hemorrhagic Fever, Korean Hantaviruses are members of the genus Orthohantavirus in the family Hantaviridae Hemorrhagic Fever and order Bunyavirales. As of 2017, 41 species of hantaviruses had officially accepted names, but there is ongoing debate about which viruses should be considered discrete species, and additional viruses have been discovered but not yet classified. Different Last Updated: September 2018 viruses tend to be associated with the two major clinical syndromes in humans, hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary (or cardiopulmonary) syndrome (HPS). However, this distinction is not absolute: viruses that are usually associated with HFRS have been infrequently linked to HPS and vice versa. A mild form of HFRS in Europe is commonly called nephropathia epidemica.
    [Show full text]
  • Escherichia Coli Saccharomyces Cerevisiae Bacillus Subtilis はB
    研究開発等に係る遺伝子組換え生物等の第二種使用等に当たって執るべき拡散防止措 置等を定める省令の規定に基づき認定宿主ベクター系等を定める件 （平成十六年一月二十九日文部科学省告示第七号） 最終改正：令和三年二月十五日文部科学省告示第十三号 （認定宿主ベクター系） 第一条 研究開発等に係る遺伝子組換え生物等の第二種使用等に当たって執るべき拡散防止 措置等を定める省令（以下「省令」という。）第二条第十三号の文部科学大臣が定める認 定宿主ベクター系は、別表第一に掲げるとおりとする。 （実験分類の区分ごとの微生物等） 第二条 省令第三条の表第一号から第四号までの文部科学大臣が定める微生物等は、別表第 二の上欄に掲げる区分について、それぞれ同表の下欄に掲げるとおりとする。 （特定認定宿主ベクター系） 第三条 省令第五条第一号ロの文部科学大臣が定める特定認定宿主ベクター系は、別表第一 の２の項に掲げる認定宿主ベクター系とする。 （自立的な増殖力及び感染力を保持したウイルス及びウイロイド） 第四条 省令別表第一第一号ヘの文部科学大臣が定めるウイルス及びウイロイドは、別表第 三に掲げるとおりとする。 別表第１（第１条関係） 区 分 名 称 宿主及びベクターの組合せ １ Ｂ１ (１) ＥＫ１ Escherichia coli K12株、B株、C株及びW株又は これら各株の誘導体を宿主とし、プラスミド又は バクテリオファージの核酸であって、接合等によ り宿主以外の細菌に伝達されないものをベクター とするもの（次項(１)のＥＫ２に該当するものを除 く。） (２) ＳＣ１ Saccharomyces cerevisiae又はこれと交雑可能な 分類学上の種に属する酵母を宿主とし、これらの 宿主のプラスミド、ミニクロモソーム又はこれら の誘導体をベクターとするもの（次項(２)のＳＣ２ に該当するものを除く。） (３) ＢＳ１ Bacillus subtilis Marburg168株、この誘導体又 はB. licheniformis全株のうち、アミノ酸若しく は核酸塩基に対する複数の栄養要求性突然変異を 有する株又は胞子を形成しない株を宿主とし、こ れらの宿主のプラスミド（接合による伝達性のな いものに限る。）又はバクテリオファージの核酸 をベクターとするもの（次項(３)のＢＳ２に該当す るものを除く。） (４) Thermus属細菌 Thermus属細菌（T. thermophilus、T. aquaticus、 T. flavus、T. caldophilus及びT. ruberに限る。） を宿主とし、これらの宿主のプラスミド又はこの 誘導体をベクターとするもの (５) Rhizobium属細菌 Rhizobium属細菌（R. radiobacter（別名Agroba- cterium tumefaciens）及びR. rhizogenes（別名 Agrobacterium rhizogenes）に限る。）を宿主と し、これらの宿主のプラスミド又はRK2系のプラ スミドをベクターとするもの (６) Pseudomonas putida Pseudomonas putida KT2440株又はこの誘導体を 宿主とし、これら宿主への依存性が高く、宿主以 外の細胞に伝達されないものをベクターとするも の (７) Streptomyces属細菌 Streptomyces属細菌（S. avermitilis、S. coel- icolor [S. violaceoruberとして分類されるS. coelicolor A3(２)株を含む]、S. lividans、S. p- arvulus、S. griseus及びS.
    [Show full text]
  • List of Codes Used to Identify Measures Reported in the QDFC
    List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports July 2018 List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports Table of Contents Table 1a: Transfusion Summary for Medicare Dialysis Patients, Codes Used for Exclusions 3 CARCINOMA 3 COAGULATION 5 HEAD/NECK CANCER 5 HEMOLYTIC OR APLASTIC ANEMIA 9 LEUKEMIA 11 LYMPHOMA 15 METASTATIC 27 MYELOMA, ETC. 29 OTHER CANCER 30 SICKLE CELL 34 SOLID ORGAN CANCER 34 Table 1b: Transfusion Summary for Medicare Dialysis Patients, Codes Used to Identify Transfusion Events .................................................................................................................. 45 REVENUE CENTER CODES 45 PROCEDURE CODES 45 VALUE CODES 46 HCPCS CODE 46 Table 2a: Vascular Access Measures (SFR and Long-Term Catheter) for Medicare Dialysis Patients Based on Medicare Claims, Codes Used for Exclusions ........................................... 46 Produced by The University of Michigan Kidney Epidemiology and Cost Center Page 1 of 135 List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports July 2018 COMA 46 END STAGE LIVER DISEASE 48 METASTATIC CANCER 48 Table 2b: Standardized Fistulae Rate (SFR) for Medicare Dialysis Patients Based on Medicare Claims, Codes Used for Prevalent Comorbidities Adjusted in Model .................................... 50 ANEMIA 50 CORONARY ARTERY DISEASE 52 CONGESTIVE HEART FAILURE 55 CEREBROVASCULAR DISEASE 56 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 68 DIABETES 69 DRUG DEPENDENCE 79 INFECTIONS (NON-VASCULAR ACCESS-RELATED): 93 PERIPHERAL VASCULAR DISEASE (INCLUDES ARTERIAL, VENOUS AND NONSPECIFIC DISEASES) 124 Table 3: Dialysis Adequacy ...................................................................................................
    [Show full text]
  • Client Services Manual Public Health Laboratory
    CLIENT SERVICES MANUAL PUBLIC HEALTH LABORATORY COUNTY OF SANTA CLARA 2220 MOORPARK AVE, 2ND FLOOR SAN JOSE, CA 95128 (P) 408.885.4272 | (F) 408.885.4275 http://www.sccgov.org/sites /sccphd/en-us/HealthProviders/Lab Patricia Dadone, Public Health Laboratory Director Sara H. Cody, MD, Health Officer and Public Health Director Table of Contents 1 GENERAL INFORMATION ............................................................................................... 1.1 ROLE .............................................................................................................................................................. 1.1 MISSION STATEMENT ..................................................................................................................................... 1.1 ABBREVIATIONS.............................................................................................................................................. 1.2 LABORATORY CERTIFICATIONS ........................................................................................................................ 1.4 CLIENT SERVICES ............................................................................................................................................ 1.5 Hours of Operation: .............................................................................................................................. 1.5 Supplies ..................................................................................................................................................
    [Show full text]
  • Ribosome Shunting, Polycistronic Translation, and Evasion of Antiviral Defenses in Plant Pararetroviruses and Beyond Mikhail M
    Ribosome Shunting, Polycistronic Translation, and Evasion of Antiviral Defenses in Plant Pararetroviruses and Beyond Mikhail M. Pooggin, Lyuba Ryabova To cite this version: Mikhail M. Pooggin, Lyuba Ryabova. Ribosome Shunting, Polycistronic Translation, and Evasion of Antiviral Defenses in Plant Pararetroviruses and Beyond. Frontiers in Microbiology, Frontiers Media, 2018, 9, pp.644. 10.3389/fmicb.2018.00644. hal-02289592 HAL Id: hal-02289592 https://hal.archives-ouvertes.fr/hal-02289592 Submitted on 16 Sep 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - ShareAlike| 4.0 International License fmicb-09-00644 April 9, 2018 Time: 16:25 # 1 REVIEW published: 10 April 2018 doi: 10.3389/fmicb.2018.00644 Ribosome Shunting, Polycistronic Translation, and Evasion of Antiviral Defenses in Plant Pararetroviruses and Beyond Mikhail M. Pooggin1* and Lyubov A. Ryabova2* 1 INRA, UMR Biologie et Génétique des Interactions Plante-Parasite, Montpellier, France, 2 Institut de Biologie Moléculaire des Plantes, Centre National de la Recherche Scientifique, UPR 2357, Université de Strasbourg, Strasbourg, France Viruses have compact genomes and usually translate more than one protein from polycistronic RNAs using leaky scanning, frameshifting, stop codon suppression or reinitiation mechanisms.
    [Show full text]
  • Identification of the Porcine Cytomegalovirus Major Capsid Protein Gene
    FULL PAPER Virology Identification of the Porcine Cytomegalovirus Major Capsid Protein Gene Vasantha RUPASINGHE1), Kiyoko IWATSUKI-HORIMOTO2), Shunji SUGII1) and Taisuke HORIMOTO2)* 1)Department of Veterinary Microbiology, Graduate School of Osaka Prefecture University, 1–1 Gakuen, Sakai, Osaka 599–8531 and 2)Division of Virology, Institute of Medical Science, University of Tokyo, 4–6–1 Shirokanedai, Minato-ku, Tokyo 108–8639, Japan (Received 13 November 2000/Accepted 14 February 2001) ABSTRACT. A major capsid protein (MCP) gene homologue of porcine cytomegalovirus (PCMV) was identified. Sequence analysis indi- cated that the PCMV MCP gene is 4,026 nucleotides in length encoding a protein of 1,341 amino acid residues. The predicted molecular weight of the PCMV MCP is 151,456 Da, equivalent to those of other herpesvirus MCP counterparts. Phylogenetic analysis using her- pesviral MCP gene sequences confirmed that PCMV is a betaherpesvirus with higher homology with human herpesvirus-6 and -7 than human and mouse cytomegaloviruses. The serum of pig experimentally infected with PCMV did not react with bacterially expressed MCP, suggesting that the PCMV MCP may not be related to the humoral immune response in the course of PCMV infection. Also, we established polymerase chain reaction (PCR) protocols using primers corresponding to MCP gene sequences for detection of PCMV infection. The PCR protocol would be effective for the diagnosis of slow-growing PCMV infection, for which traditional methods involving virus-isolation are not useful. KEY WORDS: betaherpesvirus, major capsid protein, polymerase chain reaction, porcine cytomegalovirus. J. Vet. Med. Sci. 63(6): 609–618, 2001 Porcine cyomegalovirus (PCMV), first described in 1955 established a polymerase chain reaction (PCR) protocol for [6], usually induces a silent infection in adult pigs but often specific detection of PCMV infection.
    [Show full text]